{"filings":[{"id":1673117,"accession_number":"0001683168-26-005555","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2026-07-16T00:11:52+00:00","items":["1.01","9.01"],"status":"ready","headline":"ISCO agrees to sell Lifeline Cell Technology to ATCC for $25M in cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $25M, subject to net working capital, cash, and debt adjustments; closing expected Q3 2026.","Seller must obtain stockholder consent from requisite holders; support agreements already signed for >50% voting power.","Indemnity escrow of $2.5M and adjustment escrow of $100K; post-closing adjustment process with 90-day review.","Transition services agreement to be effective at closing; non-solicitation and non-compete covenants for 5 years post-closing.","LCT develops and sells primary human cells, stem cells, and cell culture media for scientific research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1009716,"accession_number":"0001683168-26-004786","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2026-06-12T11:57:45+00:00","items":["5.07"],"status":"ready","headline":"Stockholders elect four directors at International Stem Cell annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andrey Semechkin and Russell Kern elected directors by Series D Preferred Stock with 2,457,143 votes each.","Donald A. Wright (9,288,444 for, 30,590 withheld) and Paul V. Maier (9,288,500 for, 30,534 withheld) elected by all shareholders on as-converted basis.","Annual meeting held June 11, 2026; no other proposals were considered.","All director terms run until the 2027 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119437,"accession_number":"0001683168-25-008521","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"International Stem Cell reports annual meeting voting results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Semechkin and Kern (Series D), Wright and Maier (all shares) with 7.77M votes each.","Advisory vote on executive compensation approved: 7,715,844 for, 73,393 against, 2,459 abstain.","Advisory vote on frequency of say-on-pay selected '3 Years' with 7,593,833 votes; 1-year and 2-year received 142,581 and 50,443 votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135995,"accession_number":"0001683168-25-007018","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"International Stem Cell extends CEO loan of $2.5M to Sept 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of $2.5M promissory note from CEO Andrey Semechkin from Sept 15, 2025 to Sept 15, 2026.","Original note was $2.7M issued Sept 2024; $200k repaid; outstanding principal $2.5M.","Accrued and unpaid interest of $799,064.44 carried forward, does not accrue additional interest.","Interest rate unchanged at 5.5% per annum; company may prepay without penalty.","Company's Co-Chairman and CEO is the noteholder; related-party transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205295,"accession_number":"0001683168-24-006436","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"International Stem Cell extends CEO's $2.7M loan maturity to Sept 2025 after repaying $200k","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO Dr. Andrey Semechkin loan of $2.9M extended; $200k repaid, new $2.7M unsecured note issued.","New note bears 5.5% interest, matures Sept 15, 2025, prepayable without penalty.","Accrued unpaid interest of ~$645k from prior note remains outstanding.","Related-party transaction creates direct financial obligation; Noteholder is Co-Chairman and CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276421,"accession_number":"0001683168-23-006510","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"International Stem Cell extends $2.9M CEO loan maturity to Sept 2024","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO Andrey Semechkin extended $2.9M promissory note maturity from Sept 15, 2023 to Sept 15, 2024.","Interest rate set at 4.5% per annum; note is unsecured and non-convertible.","Accrued unpaid interest on original note was approximately $518,100 as of issuance date.","Borrower may prepay the note in whole or part without penalty at any time.","Note issued in exchange for original March 15, 2023 promissory note that was maturing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294141,"accession_number":"0001683168-23-004312","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"International Stem Cell Corp holds annual meeting, elects four directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected directors Andrey Semechkin and Russell Kern (Series D Preferred holders) each with 2,457,143 for, 0 withheld.","Directors Donald A. Wright and Paul V. Maier elected with 7,833,624 and 7,834,844 for, vs 44,091 and 42,871 withheld.","No broker non-votes occurred; all four directors will serve until the 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314751,"accession_number":"0001683168-23-001546","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"International Stem Cell extends $2.9M CEO loan maturity to September 2023","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal $2.9M from CEO Andrey Semechkin; maturity extended from Mar 15 to Sep 15, 2023.","Interest rate 4.5% per annum; note is unsecured, non-convertible, prepayable without penalty.","Unpaid interest on original note approx. $451,000 as of March 15, 2023.","Loan is a replacement for prior note issued Sept 15, 2022; no new proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350605,"accession_number":"0001683168-22-006449","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2022-09-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"CEO extends $2.9M loan maturity to March 2023 at 4.5% interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Sep 15, 2022, International Stem Cell Corp. extended maturity of $2.9M loan from CEO Andrey Semechkin to Mar 15, 2023.","The loan originally issued Mar 1, 2022 was due Sep 15, 2022; replaced with new unsecured, non-convertible note.","Interest rate remains 4.5% per annum; company may prepay without penalty.","Dr. Semechkin is Co-Chairman and CEO; transaction is a related-party extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367787,"accession_number":"0001683168-22-004317","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annual meeting results: directors elected, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Andrey Semechkin and Russell Kern elected by Series D Preferred Stock holders (2,457,143 votes each).","Donald A. Wright and Paul V. Maier elected by all voting shares (7,648,278 and 7,648,339 votes for, respectively).","Advisory vote on executive compensation passed with 7,544,159 FOR, 200,375 AGAINST, 5,027 abstentions.","No broker non-votes reported for either proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367786,"accession_number":"0001683168-22-003021","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2022-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"International Stem Cell appoints Dr. Russell Kern as principal financial officer; granted 1M options, salary $130K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Russell Kern appointed principal financial officer effective April 25, 2022.","He continues as EVP and Chief Scientific Officer.","Granted options to purchase 1,000,000 shares of common stock.","Salary increased to $130,000 per year.","Biographical information incorporated from 2022 Proxy Statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387141,"accession_number":"0001564590-22-008509","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"International Stem Cell extends $2.9M CEO loan maturity to Sept 15, 2022","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Extended maturity of $2.9M promissory note from CEO Andrey Semechkin to Sept 15, 2022 (was Mar 15, 2022).","Note is unsecured, non-convertible, bears 4.5% annual interest.","Loan originated Jan 13, 2022; this new note replaces the original on same principal.","CEO Semechkin is Co-Chairman and CEO; transaction is a related-party financing.","Company may prepay the note at any time without penalty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387140,"accession_number":"0001564590-22-003423","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"International Stem Cell Corp's CFO Sophia Garnette resigns effective April 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sophia Garnette, Principal Financial Officer and VP of Legal Affairs and Operations, submitted resignation.","Resignation effective April 1, 2022.","Company evaluating alternatives for successor principal financial officer.","Garnette will assist with transition once successor is identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387139,"accession_number":"0001564590-22-001352","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2022-01-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"International Stem Cell issues $2.9M promissory note to CEO Andrey Semechkin for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Unsecured, non-convertible note for $2,900,000 issued to CEO/Co-Chairman on Jan 13, 2022.","Replaces prior $2,650,000 note plus additional $250,000 provided by Dr. Semechkin.","Interest rate of 4.5% per annum; principal and accrued interest due March 15, 2022.","Borrower may prepay without penalty at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405062,"accession_number":"0001564590-21-061431","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2021-12-28T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"International Stem Cell terminates headquarters lease early; no termination fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 5950 Priestly Drive, Carlsbad, CA terminated effective no later than Dec 31, 2021.","Original lease was set to expire March 1, 2023.","Landlord is S Real Estate Holdings LLC, owned by EVP/CSO Russell Kern and formerly by CEO Andrey Semechkin.","No termination fee payable; December 2021 base rent obligation released.","Company must surrender premises per Termination Agreement section 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405061,"accession_number":"0001564590-21-053192","cik":1355790,"company_name":"International Stem Cell CORP","ticker":"ISCO","form_type":"8-K","filed_at":"2021-11-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"International Stem Cell signs lease for new HQ in San Diego; related-party transaction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease covers 7,260 sq ft at 9745 Businesspark Ave, San Diego, consolidating Carlsbad and Oceanside offices.","Initial combined base rent $10,890/month, escalating to $12,933.90 by lease end (Dec 31, 2026).","Term starts Nov 1, 2021, for 5 years and 2 months through Dec 31, 2026.","Co-tenant S Real Estate Holdings LLC owned by EVP/CSO Dr. Russell Kern, previously owned by CEO Dr. Andrey Semechkin.","Company also responsible for insurance, maintenance, taxes, and operating expenses per lease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1360746.1621621621,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}